Welcome Introduction: The Evolving and Complex Therapeutic Landscape for Multiple Sclerosis: Achieving the Ideal Balance Between Safety and Efficacy for Long-Term Treatment In the Managed Care Setting
Bruce A. Cree, MD, PhD, MCR

Pharmacy and Medical Directors, and Neurologist Colleagues, Discuss Emerging Concerns, Challenges, and Strategic Needs for Optimizing MS Care in the Managed Care Environment
Group Discussion

Trial-Based Evidence for First Line Therapy with Immune- Modulating Agents: From Mechanisms to Therapy—Landmark Studies, Long-Term Safety Data, and Clinical Experience with IMTs in the Managed Care Environment
Bruce A. Cree, MD, PhD, MCR

Pharmacy and Medical Directors, and Neurologist Colleagues, Discuss Current Strategies and MS Treatment Paradigms Using IMT-Based Platforms for Initial Therapy for MS in the Managed Care Setting
Group Discussion

The Emergence of Oral Immunosuppressive and Other Agents for MS: What Do We Know (or Not Know) About Their Safety and Efficacy?
Suhayl Dhib-Jalbut, MD

Pharmacy and Medical Directors, and Neurologist Colleagues, Discuss Complexity of Evolving Agents for MS, Approaches to Pharmacovigilance, Case Management, and The Challenges of Balancing Efficacy with Safety Across the Immunosuppressive Spectrum of Emerging Agents
Group Discussion

The Changing MS Therapeutic Landscape: Perspectives of an MS-Focused Pharmacist—How Will We Need to Adapt to and Analyze the New Generation of MS Therapies?
Ronald DeBellis, PharmD

Pharmacy and Medical Directors, and their Neurologist Colleagues, Discuss the Near Future of MS Care
Group Discussion

The Role of Comparative Effectiveness Guidelines, Long Term Safety Considerations, and Monitoring Costs for Evaluating Therapies for MS
Jacquelyn Bainbridge, PharmD, FCCP

Pharmacy and Medical Directors Discuss the Complexities, Challenges and Solutions for Making Sense and Adapting to the Emerging Landscape—and New Risk/Benefit Equations—of New Oral Agents for MS. Will Patient Registries Be Required?
Group Discussion